Thera European filing by end Q3

Thera press release says their regulatory meetings last week went well, they don’t need any additional data to pursue a filing with the European Medicines Agency (EMA) for Trogarzo™ and expect to complete filing by the end of 2018 Q3.

The HIV-1 MDR patient population in Europe is estimated to be similar to the USA. European approval would therefore greatly increase the patient target population for Trogarzo. Thera has a similar deal with TaiMed for the European territory as they do with the American territory. Trogarzo received FDA approval March 6, 2018.

https://globenewswire.com/news-release/2018/04/24/1486420/0/…